REVLIMID (Lenalidomide) Capsules 25mg

Manufacturer
Celgene International Sarl(SWITZERLAND)

Registraction Number
MAL12040007ARZ

Content:
REVLIMID (Lenalidomide) Capsules 25mg contain 25 mg of lenalidomide, which is an immunomodulatory agent used to treat multiple myeloma and certain other conditions.
Indications:

• Multiple Myeloma: Treatment of adults with multiple myeloma in combination with dexamethasone, or as maintenance therapy after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells).
• Myelodysplastic Syndromes (MDS): Treatment of adults with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality.
• Mantle Cell Lymphoma (MCL): Treatment of adults with MCL that has relapsed or progressed after two prior therapies, one of which included bortezomib.
• Follicular Lymphoma (FL): Treatment of adults with previously treated FL in combination with a rituximab product.
• Marginal Zone Lymphoma (MZL): Treatment of adults with previously treated MZL in combination with a rituximab product.

1. Administration: Take orally, as directed by your doctor.
2. Dosage: Follow your doctor's prescription. The dosage may vary based on the patient's condition and response to treatment.
3. Timing: Take it at the same time each day to help you remember.
4. Monitoring: Regular monitoring of blood counts and other parameters is essential.